Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 52

1.

Ehrlichia-Induced Hemophagocytic Lymphohistiocytosis: A Case Series and Review of Literature.

Otrock ZK, Gonzalez MD, Eby CS.

Blood Cells Mol Dis. 2015 Oct;55(3):191-3. doi: 10.1016/j.bcmd.2015.06.009. Epub 2015 Jun 23.

PMID:
26227842
2.

Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis.

Otrock ZK, Eby CS.

Am J Hematol. 2015 Mar;90(3):220-4. doi: 10.1002/ajh.23911. Epub 2015 Jan 16.

PMID:
25469675
3.

A randomized phase II trial investigating the effect of platelet function inhibition on circulating tumor cells in patients with metastatic breast cancer.

Roop RP, Naughton MJ, Van Poznak C, Schneider JG, Lammers PE, Pluard TJ, Johnson F, Eby CS, Weilbaecher KN.

Clin Breast Cancer. 2013 Dec;13(6):409-15. doi: 10.1016/j.clbc.2013.08.006.

4.

A pharmacogenetic versus a clinical algorithm for warfarin dosing.

Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, Rosenberg YD, Eby CS, Madigan RA, McBane RB, Abdel-Rahman SZ, Stevens SM, Yale S, Mohler ER 3rd, Fang MC, Shah V, Horenstein RB, Limdi NA, Muldowney JA 3rd, Gujral J, Delafontaine P, Desnick RJ, Ortel TL, Billett HH, Pendleton RC, Geller NL, Halperin JL, Goldhaber SZ, Caldwell MD, Califf RM, Ellenberg JH; COAG Investigators.

N Engl J Med. 2013 Dec 12;369(24):2283-93. doi: 10.1056/NEJMoa1310669. Epub 2013 Nov 19.

5.

Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial.

Kimmel SE, French B, Anderson JL, Gage BF, Johnson JA, Rosenberg YD, Geller NL, Kasner SE, Eby CS, Joo J, Caldwell MD, Goldhaber SZ, Hart RG, Cifelli D, Madigan R, Brensinger CM, Goldberg S, Califf RM, Ellenberg JH.

Am Heart J. 2013 Sep;166(3):435-41. doi: 10.1016/j.ahj.2013.04.009. Epub 2013 Jul 12. Erratum in: Am Heart J. 2014 Feb;167(2):281. Dosage error in article text.

6.

D-dimer: simple test, tough problems.

Olson JD, Cunningham MT, Higgins RA, Eby CS, Brandt JT.

Arch Pathol Lab Med. 2013 Aug;137(8):1030-8. doi: 10.5858/arpa.2012-0296-CP.

PMID:
23899057
7.

Warfarin replacements: good for patients, challenging for laboratories.

Eby CS.

Clin Chem. 2013 May;59(5):732-4. doi: 10.1373/clinchem.2013.203174. Epub 2013 Mar 13. No abstract available.

8.

Linear relationship between lymphocyte counts in peripheral blood and buffy coat collected during extracorporeal photopheresis.

Liu C, Shah K, Dynis M, Eby CS, Grossman BJ.

Transfusion. 2013 Nov;53(11):2635-43. doi: 10.1111/trf.12114. Epub 2013 Feb 17.

PMID:
23414109
9.

External quality assurance of fibrinogen assays using normal plasma: results of the 2008 College of American Pathologists proficiency testing program in coagulation.

Cunningham MT, Olson JD, Chandler WL, Van Cott EM, Eby CS, Teruya J, Hollensead SC, Adcock DM, Allison PM, Kottke-Marchant KK, Smith MD.

Arch Pathol Lab Med. 2012 Jul;136(7):789-95. doi: 10.5858/arpa.2011-0322-OA.

PMID:
22742551
10.

Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy.

Horne BD, Lenzini PA, Wadelius M, Jorgensen AL, Kimmel SE, Ridker PM, Eriksson N, Anderson JL, Pirmohamed M, Limdi NA, Pendleton RC, McMillin GA, Burmester JK, Kurnik D, Stein CM, Caldwell MD, Eby CS, Rane A, Lindh JD, Shin JG, Kim HS, Angchaisuksiri P, Glynn RJ, Kronquist KE, Carlquist JF, Grice GR, Barrack RL, Li J, Gage BF.

Thromb Haemost. 2012 Feb;107(2):232-40. doi: 10.1160/TH11-06-0388. Epub 2011 Dec 21.

11.

Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design.

Do EJ, Lenzini P, Eby CS, Bass AR, McMillin GA, Stevens SM, Woller SC, Pendleton RC, Anderson JL, Proctor P, Nunley RM, Davila-Roman V, Gage BF.

Pharmacogenomics J. 2012 Oct;12(5):417-24. doi: 10.1038/tpj.2011.18. Epub 2011 May 24.

12.

External quality assurance of antithrombin, protein C, and protein s assays: results of the College of American Pathologists proficiency testing program in thrombophilia.

Cunningham MT, Olson JD, Chandler WL, Van Cott EM, Eby CS, Teruya J, Hollensead SC, Adcock DM, Allison PM, Kottke-Marchant KK, Smith MD.

Arch Pathol Lab Med. 2011 Feb;135(2):227-32. doi: 10.1043/1543-2165-135.2.227.

PMID:
21284443
13.

Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients.

Ford BA, Eby CS, Scott MG, Coyne DW.

Kidney Int. 2010 Oct;78(8):769-73. doi: 10.1038/ki.2010.254. Epub 2010 Jul 28.

PMID:
20668427
14.

Blast flagging with the UniCel DxH 800 Coulter Cellular Analysis System.

Barnes PW, Eby CS, Shimer G.

Lab Hematol. 2010 Jun;16(2):23-5. doi: 10.1532/LH96.09015.

PMID:
20534427
15.

A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.

Voora D, Koboldt DC, King CR, Lenzini PA, Eby CS, Porche-Sorbet R, Deych E, Crankshaw M, Milligan PE, McLeod HL, Patel SR, Cavallari LH, Ridker PM, Grice GR, Miller RD, Gage BF.

Clin Pharmacol Ther. 2010 Apr;87(4):445-51. doi: 10.1038/clpt.2009.291. Epub 2010 Mar 3.

16.

Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy.

Ferder NS, Eby CS, Deych E, Harris JK, Ridker PM, Milligan PE, Goldhaber SZ, King CR, Giri T, McLeod HL, Glynn RJ, Gage BF.

J Thromb Haemost. 2010 Jan;8(1):95-100. doi: 10.1111/j.1538-7836.2009.03677.x. Epub 2009 Oct 30.

17.

Counterpoint: pharmacogenetic-based initial dosing of warfarin: not ready for prime time.

Eby CS.

Clin Chem. 2009 Apr;55(4):712-4. doi: 10.1373/clinchem.2008.115972. Epub 2009 Feb 20. No abstract available.

18.

Variability of ferritin measurements in chronic kidney disease; implications for iron management.

Ford BA, Coyne DW, Eby CS, Scott MG.

Kidney Int. 2009 Jan;75(1):104-10. doi: 10.1038/ki.2008.526. Epub 2008 Oct 8.

PMID:
18843257
19.

Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.

Lenzini PA, Grice GR, Milligan PE, Dowd MB, Subherwal S, Deych E, Eby CS, King CR, Porche-Sorbet RM, Murphy CV, Marchand R, Millican EA, Barrack RL, Clohisy JC, Kronquist K, Gatchel SK, Gage BF.

J Thromb Haemost. 2008 Oct;6(10):1655-62. doi: 10.1111/j.1538-7836.2008.03095.x. Epub 2008 Jul 24.

20.

Evaluation of a prolonged prothrombin time.

Hood JL, Eby CS.

Clin Chem. 2008 Apr;54(4):765-8; discussion 768-9. doi: 10.1373/clinchem.2007.100818. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk